ESR1 and breast carcinoma: Indeed, a full clinical response has been achieved after a patient with metastatic AR-positive TNBC was treated for 4 months with bicalutamide, a first-generation nonsteroidal AR inhibitor [20], and a 19% clinical benefit rate (CBR) has been observed after 424 patients with ER/PR-negative breast cancers were treated with bicalutamide for 6 months [21].